-
Mashup Score: 0FDA approves mepolizumab for COPD with eosinophilic phenotype - 9 hour(s) ago
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, according to a GSK press release.This is the second biologic approved as an add-on maintenance treatment for COPD. As Healio previously reported, the FDA approved dupilumab (Dupixent; Regeneron, Sanofi) as an add-on maintenance treatment in the same patient population in
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0Mepolizumab lowers severe exacerbation risk in COPD, type 2 inflammation at 104 weeks - 1 day(s) ago
SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 weeks, according to study findings.This secondary analysis of the MATINEE trial, which included patients “regardless of the presence or absence of chronic bronchitis or emphysema, and regardless of
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Patients with #COPD and type 2 inflammation receiving #mepolizumab vs. placebo had decreased moderate and severe #exacerbation rates and fewer ED visits per exacerbation at 104 weeks, according to data at #ATS2025. @atscommunity @katztemplemed @TempleLung https://t.co/P62IL8faaX
-
-
Mashup Score: 0
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, according to a GSK press release.This is the second biologic approved as an add-on maintenance treatment for COPD. As Healio previously reported, the FDA approved dupilumab (Dupixent; Regeneron, Sanofi) as an add-on maintenance treatment in the same patient population in
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
🚨The #FDA granted approval to #mepolizumab for treating adults with inadequately controlled #COPD and an #eosinophilic phenotype, according to a @GSK press release. 💬Mike Hess (@MUCOPHILE), MPH, RRT, RPFT, @COPDFoundation, shares his perspective. https://t.co/sZo5onlBkH
-
-
Mashup Score: 0Mepolizumab lowers severe exacerbation risk in COPD, type 2 inflammation at 104 weeks - 1 day(s) ago
SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 weeks, according to study findings.This secondary analysis of the MATINEE trial, which included patients “regardless of the presence or absence of chronic bronchitis or emphysema, and regardless of
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Patients with #COPD and type 2 inflammation receiving #mepolizumab vs. placebo had decreased moderate and severe #exacerbation rates and fewer ED visits per exacerbation at 104 weeks, according to data at #ATS2025. @atscommunity @katztemplemed @TempleLung https://t.co/P62IL8faaX
-
-
Mashup Score: 0
SAN FRANCISCO — Patient groups with reduced odds for extracorporeal membrane oxygenation had shorter travel distances to a hospital with this resource, according to data presented at the American Thoracic Society International Conference.“I think we often assume a resource is more accessible if it is within a patient’s local environment, but this study suggests it is much more
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
At #ATS2025: Patient groups with reduced odds for #ECMO had shorter travel distances🚗 to a hospital🏥 with this resource. @atscommunity @CU_PSCCM https://t.co/XzHKY46gz9
-
-
Mashup Score: 0
SAN FRANCISCO — Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, according to an abstract presented at the American Thoracic Society International Conference.Persistence rates varied depending on the biologic, Justin Kwiatek, PharmD, senior director and U.S. medical affairs lead, respiratory biologics, GSK, said
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
âť—Patients with #asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, Dr. Justin Kwiatek of @GSK said at #ATS2025. @atscommunity https://t.co/MHK2Eknumy
-
-
Mashup Score: 0
SAN FRANCISCO — Patient groups with reduced odds for extracorporeal membrane oxygenation had shorter travel distances to a hospital with this resource, according to data presented at the American Thoracic Society International Conference.“I think we often assume a resource is more accessible if it is within a patient’s local environment, but this study suggests it is much more
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
At #ATS2025: Patient groups with reduced odds for #ECMO had shorter travel distances🚗 to a hospital🏥 with this resource. @atscommunity @CU_PSCCM https://t.co/XzHKY46gz9
-
-
Mashup Score: 0
SAN FRANCISCO — Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, according to an abstract presented at the American Thoracic Society International Conference.Persistence rates varied depending on the biologic, Justin Kwiatek, PharmD, senior director and U.S. medical affairs lead, respiratory biologics, GSK, said
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
âť—Patients with #asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, Dr. Justin Kwiatek of @GSK said at #ATS2025. @atscommunity https://t.co/MHK2Eknumy
-
-
Mashup Score: 3Women vs. men with ILD have lower odds for mortality in ICU - 3 day(s) ago
SAN FRANCISCO — Among adults with interstitial lung disease requiring ICU care, women faced a lower adjusted likelihood for mortality vs. men, according to research presented at the American Thoracic Society International Conference.“Findings in this study suggest we should be aware that gender could influence prognosis,” Matthew Viggiano, MD, medical resident at Temple
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
At #ATS2025: Among adults with #ILD requiring #ICU care, women👩 faced a lower adjusted likelihood for mortality vs. men👨. @atscommunity @TempleHealth https://t.co/PeThuibTtB
-
-
Mashup Score: 3Women vs. men with ILD have lower odds for mortality in ICU - 3 day(s) ago
SAN FRANCISCO — Among adults with interstitial lung disease requiring ICU care, women faced a lower adjusted likelihood for mortality vs. men, according to research presented at the American Thoracic Society International Conference.“Findings in this study suggest we should be aware that gender could influence prognosis,” Matthew Viggiano, MD, medical resident at Temple
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
At #ATS2025: Among adults with #ILD requiring #ICU care, women👩 faced a lower adjusted likelihood for mortality vs. men👨. @atscommunity @TempleHealth https://t.co/PeThuibTtB
-
🚨The #FDA granted approval to #mepolizumab for treating adults with inadequately controlled #COPD and an #eosinophilic phenotype, according to a @GSK press release. 💬Mike Hess (@MUCOPHILE), MPH, RRT, RPFT, @COPDFoundation, shares his perspective. https://t.co/sZo5onlBkH